Company
Phathom
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
4
4 still marketed
Novel approvals
2
Approvals since 2021
4
Originals and new uses
Phase 3 trials
4
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Voquezna approved Jul 17, 2024
- Voquezna approved NovelNov 1, 2023
- Voquezna Dual Pak approved Priority reviewMay 3, 2022
- Voquezna Triple Pak approved NovelPriority reviewMay 3, 2022
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 WeeksPivotal-lookingRecruiting
Phathom Pharmaceuticals, Inc.Industry
NCT07752407 · 500 participants (planned) · Start Sep 25, 2026 · Primary completion Oct 20, 2027
Drug: Vonoprazan; Placebo · For: Symptomatic Non-erosive Gastroesophageal Reflux Disease
Sites: Phoenix, Arizona; Chula Vista, California; Lomita, California · 26 sites in all
Marketed drugs (4)
Newest FDA action first.
- Voquezna Vonoprazan Fumarate · 2023
- Voquezna Dual Pak Amoxicillin, Vonoprazan Fumarate · 2022
- Voquezna Triple Pak Amoxicillin, Clarithromycin, Vonoprazan Fumarate · 2022
- Voquezna Vonoprazan Fumarate · 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.